Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	9.35B +211.9%
Revenue (ttm)	1.56B +12.8%
Net Income	112.17M +51.6%
EPS	0.50 +47.6%
Shares Out	242.81M
PE Ratio	77.01
Forward PE	n/a
Dividend	0.16 (0.39%)
Ex-Dividend Date	Jun 25, 2025

Volume	21,510,928
Open	38.50
Previous Close	38.50
Day's Range	36.87 - 38.80
52-Week Range	16.72 - 70.39
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,370
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.